Teva's R&D Chief Eric Hughes Departs as Company Initiates Leadership Search

  • Dr. Eric Hughes, Teva's Executive Vice President of Global R&D and Chief Medical Officer, will depart the company after accepting an external offer.
  • David Gardiner, MD, will serve as interim R&D transition lead, reporting directly to CEO Richard Francis.
  • Teva's R&D strategy and priorities remain unchanged, with a focus on delivering $6–7 billion in innovative medicines revenue by 2030.
  • The company will begin a comprehensive search for a permanent successor immediately.

Teva's leadership transition in R&D comes at a critical juncture as the company seeks to pivot from generics to a high-velocity biopharmaceutical model. The departure of Dr. Hughes, who played a key role in transforming the R&D organization, raises questions about the stability of Teva's strategic ambitions. The company's ability to attract a strong successor and maintain its pipeline momentum will be crucial in a competitive pharmaceutical landscape.

Leadership Stability
How quickly Teva can identify and integrate a permanent R&D leader to maintain momentum in its pipeline development.
Pipeline Execution
Whether the company can sustain its R&D commitments and deliver on its $6–7 billion revenue target by 2030.
Strategic Focus
The pace at which Teva advances its innovative medicines portfolio amid broader market and geopolitical challenges.